NL-OMON36928CompletedPhase 2
A multicenter, randomized, partially blinded, placebo-controlled clinical trial to evaluate the effect on primary dysmenorrheal of vaginal rings with an average daily release of 700 µg nomegestrol acetate (NOMAC) and 300 µg estradiol (E2), or 900 µg nomegestrol acetate (NOMAC) and 300 µg estradiol (E2), or 100 µg etonogestrel (ENG) and 300 µg E2, or 125 µg etonogestrel (ENG) and 300 µg E2 - MK8342B-057
Merck Sharp & Dohme (MSD)0 sites35 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 35
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •1. Subject must be willing and able to provide written informed consent for the trial.
- •2. Subject must be female.
- •3. Subject must be >=18 to <= 50 years of age.
- •4. Subject must have a body mass index (BMI) >=18 and <=35.
- •5. Subject must have an established diagnosis of primary dysmenorrhea, characterized by menstrual pain in the absence of detectable pelvic pathology (eg, endometriosis, fibroids, pelvic inflammatory disease).
- •6. Each non-sterilized sexually active subject of child-bearing potential must agree to use condoms for contraception during the entire screening period, treatment period, and post-treatment period until the final study visit.
- •7. Subject using a hormonal contraceptive (combined or progestin-only), or a non-hormonal IUD, at the screening visit must agree to stop using that method.
- •8. Subject has regular menstrual cycles ranging from 24 to 32 days in length (to be confirmed at the randomization visit following completion of a baseline menstrual cycle).
Exclusion Criteria
- •1. Subject has any contraindication to the use of contraceptive steroids.
- •2. Subject has secondary dysmenorrhea - ie, menstrual pain in the presence of detectable pelvic pathology (eg, endometriosis, fibroids, pelvic inflammatory disease).
- •3. Subject has not had spontaneous menstruation following a delivery or abortion at the screening visit.
- •4. The subject is breastfeeding or has not had spontaneous menstruation following completion of breastfeeding at the screening visit.
- •5. Subject has a history of malignancy <=5 years prior to signing the informed consent, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
- •6. Subject had a documented abnormal cervical smear result within 6 months prior to the screening visit.
- •7. Subject routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Vaginal ring dysmenorrhea feasibility trial.EUCTR2012-002449-40-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.450
Active, not recruiting
Not Applicable
Vaginal ring dysmenorrhea feasibility trial.This study will investigate the use of 4 doses of combined contraceptives (a progestin with an estrogen) in a vaginal ring dosage form for the treatment of dysmenorrhea (menstrual cramping pain). A placebo control arm will also be utilized.MedDRA version: 14.1Level: LLTClassification code 10013934Term: DysmenorrheaSystem Organ Class: 100000004872EUCTR2012-002449-40-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.450
Active, not recruiting
Not Applicable
Vaginal ring dysmenorrhea feasibility trial.EUCTR2012-002449-40-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.450
Active, not recruiting
Phase 1
Vaginal ring dysmenorrhea feasibility trial.This study will investigate the use of 4 doses of combined contraceptives (a progestin with an estrogen) in a vaginal ring dosage form for the treatment of dysmenorrhea (menstrual cramping pain). A placebo control arm will also be utilized.MedDRA version: 15.0 Level: LLT Classification code 10013934 Term: Dysmenorrhea System Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2012-002449-40-NOMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.439
Active, not recruiting
Phase 1
Vaginal ring dysmenorrhea feasibility trial.This study will investigate the use of 4 doses of combined contraceptives (a progestin with an estrogen) in a vaginal ring dosage form for the treatment of dysmenorrhea (menstrual cramping pain). A placebo control arm will also be utilized.EUCTR2012-002449-40-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.439